EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole

Authors

  • Maiken Cavling Arendrup,

    Corresponding author
    1. Unit of Mycology, Department of Microbiology & Infection Control, Statens Serum Institute, Copenhagen, Denmark
    • Correspondence: M. C. Arendrup, Unit of Mycology, Department of Microbiology & Infection Control, Statens Serum Institute, Artillerivej 5, DK-2300 Copenhagen, Denmark.

      Tel.: (+45) 22632785. Fax: (+45) 32683130.

      E-mail: maca@ssi.dk or maiken@arendrup.dk

    Search for more papers by this author
  • Manuel Cuenca-Estrella,

    1. Mycology, National Center for Microbiology, Madrid, Spain
    Search for more papers by this author
  • Cornelia Lass-Flörl,

    1. Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria
    Search for more papers by this author
  • William W. Hope,

    1. Department of Molecular and Clinical Pharmacology, The University of Liverpool, Liverpool, UK
    Search for more papers by this author
  • The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)

    Search for more papers by this author
    • EUCAST-AFST: MC Arendrup (Chairman, Denmark), WW Hope (Secretary), C Lass-Flörl, Steering Committee (Austria), M Cuenca-Estrella, Steering Committee (Spain), S Arikan-Akdagli (Turkey), F Barchiesi (Italy), J Bille (Switzerland), E Chryssanthou (Sweden), P Gaustad (Norway), A Groll (Germany), H Järv (Estonia), N Klimko (Russia), P Koukila-Kähkölä (Finland), K Lagrou (Belgium), O Lortholary (France), C Moore (United Kingdom), A Velegraki (Greece), PV Verweij (The Netherlands).

Summary

The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for micafungin and revised breakpoints for anidulafungin and fluconazole for Candida spp. This Technical Note is based on the corresponding rationale documents (http://www.eucast.org). The micafungin breakpoints are based on PK data, animal PK/PD data, microbiological data and clinical experience. The anidulafungin breakpoints for C. parapsilosis and fluconazole breakpoints for C. glabrata have been modified to species-specific values that categorise the wild-type as intermediate to accommodate use of these compounds in some clinical situations.

Ancillary